79 related articles for article (PubMed ID: 8258997)
41. Antibody delivery and effector cell activation in a phase II trial of recombinant gamma-interferon and the murine monoclonal antibody CO17-1A in advanced colorectal carcinoma.
Weiner LM; Moldofsky PJ; Gatenby RA; O'Dwyer J; O'Brien J; Litwin S; Comis RL
Cancer Res; 1988 May; 48(9):2568-73. PubMed ID: 3128400
[TBL] [Abstract][Full Text] [Related]
42. Induction of macrophage tumoricidal activity by granulocyte-macrophage colony-stimulating factor.
Grabstein KH; Urdal DL; Tushinski RJ; Mochizuki DY; Price VL; Cantrell MA; Gillis S; Conlon PJ
Science; 1986 Apr; 232(4749):506-8. PubMed ID: 3083507
[TBL] [Abstract][Full Text] [Related]
43. Pharmacokinetics of human granulocyte-macrophage colony-stimulating factor using a sensitive immunoassay.
Cebon J; Dempsey P; Fox R; Kannourakis G; Bonnem E; Burgess AW; Morstyn G
Blood; 1988 Oct; 72(4):1340-7. PubMed ID: 3048442
[TBL] [Abstract][Full Text] [Related]
44. Leucovorin and 5-fluorouracil as a treatment for disseminated cancer of the pancreas and unknown primary tumors.
Bruckner HW; Crown J; McKenna A; Hart R
Cancer Res; 1988 Oct; 48(19):5570-2. PubMed ID: 3046742
[TBL] [Abstract][Full Text] [Related]
45. The molecular biology and functions of the granulocyte-macrophage colony-stimulating factors.
Metcalf D
Blood; 1986 Feb; 67(2):257-67. PubMed ID: 3002522
[TBL] [Abstract][Full Text] [Related]
46. CD16. Developmentally regulated IgG Fc receptors on cultured human monocytes.
Clarkson SB; Ory PA
J Exp Med; 1988 Feb; 167(2):408-20. PubMed ID: 2964496
[TBL] [Abstract][Full Text] [Related]
47. Two distinct classes of IgG Fc receptors on a human monocyte line (U937) defined by differences in binding of murine IgG subclasses at low ionic strength.
Jones DH; Looney RJ; Anderson CL
J Immunol; 1985 Nov; 135(5):3348-53. PubMed ID: 2931481
[TBL] [Abstract][Full Text] [Related]
48. Treatment of patients with advanced colorectal carcinomas with fluorouracil alone, high-dose leucovorin plus fluorouracil, or sequential methotrexate, fluorouracil, and leucovorin: a randomized trial of the Northern California Oncology Group.
Valone FH; Friedman MA; Wittlinger PS; Drakes T; Eisenberg PD; Malec M; Hannigan JF; Brown BW
J Clin Oncol; 1989 Oct; 7(10):1427-36. PubMed ID: 2789272
[TBL] [Abstract][Full Text] [Related]
49. Granulocyte-monocyte-colony-stimulating factor augments the cytotoxic capacity of lymphocytes and monocytes in antibody-dependent cellular cytotoxicity.
Masucci G; Wersäll P; Ragnhammar P; Mellstedt H
Cancer Immunol Immunother; 1989; 29(4):288-92. PubMed ID: 2665935
[TBL] [Abstract][Full Text] [Related]
50. Subcutaneous granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome: toxicity, pharmacokinetics, and hematological effects.
Thompson JA; Lee DJ; Kidd P; Rubin E; Kaufmann J; Bonnem EM; Fefer A
J Clin Oncol; 1989 May; 7(5):629-37. PubMed ID: 2651578
[TBL] [Abstract][Full Text] [Related]
51. Fluorouracil and recombinant alfa-2a-interferon: an active regimen against advanced colorectal carcinoma.
Wadler S; Schwartz EL; Goldman M; Lyver A; Rader M; Zimmerman M; Itri L; Weinberg V; Wiernik PH
J Clin Oncol; 1989 Dec; 7(12):1769-75. PubMed ID: 2585018
[TBL] [Abstract][Full Text] [Related]
52. Cytotoxicity mediated by human Fc receptors for IgG.
Fanger MW; Shen L; Graziano RF; Guyre PM
Immunol Today; 1989 Mar; 10(3):92-9. PubMed ID: 2525910
[TBL] [Abstract][Full Text] [Related]
53. Treatment of advanced colorectal cancer.
Abbruzzese JL; Levin B
Hematol Oncol Clin North Am; 1989 Mar; 3(1):135-53. PubMed ID: 2465291
[TBL] [Abstract][Full Text] [Related]
54. Phase I evaluation of a combination of monoclonal antibody R24 and interleukin 2 in patients with metastatic melanoma.
Bajorin DF; Chapman PB; Wong G; Coit DG; Kunicka J; Dimaggio J; Cordon-Cardo C; Urmacher C; Dantes L; Templeton MA
Cancer Res; 1990 Dec; 50(23):7490-5. PubMed ID: 2253196
[TBL] [Abstract][Full Text] [Related]
55. Human IgE, IgG and IgA antibody responses to T101, a murine monoclonal antibody against human lymphocytes: implications for pathogenesis, risk and avoidance of adverse immunologic reactions.
Dykewicz MS; Cranberg JA; Patterson R; Rosen ST; Shaughnessy MA; Zimmer AM
Int Arch Allergy Appl Immunol; 1990; 92(2):131-7. PubMed ID: 2242927
[TBL] [Abstract][Full Text] [Related]
56. Preoperative cell-mediated immune function and the prognosis of patients with gastric carcinoma.
Akiyoshi T; Koba F; Arinaga S; Ueo H
J Surg Oncol; 1990 Nov; 45(3):137-42. PubMed ID: 2232803
[TBL] [Abstract][Full Text] [Related]
57. Granulocyte-monocyte colony-stimulating-factor augments the interleukin-2-induced cytotoxic activity of human lymphocytes in the absence and presence of mouse or chimeric monoclonal antibodies (mAb 17-1A).
Masucci G; Ragnhammar P; Wersäll P; Mellstedt H
Cancer Immunol Immunother; 1990; 31(4):231-5. PubMed ID: 2199042
[TBL] [Abstract][Full Text] [Related]
58. Comparison of the effects of IL-3, granulocyte-macrophage colony-stimulating factor, and macrophage colony-stimulating factor in supporting monocyte differentiation in culture. Analysis of macrophage antibody-dependent cellular cytotoxicity.
Young DA; Lowe LD; Clark SC
J Immunol; 1990 Jul; 145(2):607-15. PubMed ID: 2142182
[TBL] [Abstract][Full Text] [Related]
59. A phase II trial of murine monoclonal antibody 17-1A and interferon-gamma: clinical and immunological data.
Saleh MN; LoBuglio AF; Wheeler RH; Rogers KJ; Haynes A; Lee JY; Khazaeli MB
Cancer Immunol Immunother; 1990; 32(3):185-90. PubMed ID: 2126988
[TBL] [Abstract][Full Text] [Related]
60. Humoral and cellular responses of colorectal cancer patients treated with monoclonal antibodies and interferon gamma.
Blottiere HM; Douillard JY; Koprowski H; Steplewski Z
Cancer Immunol Immunother; 1990; 32(1):29-37. PubMed ID: 2126982
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
